ANTEOTECH LTD — Interim / Quarterly Report 2016

Apr 28, 2016

Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Name of entity Anteo Diagnostics Limited ACN or ARBN Quarter ended (“current quarter”)	Name of entity Anteo Diagnostics Limited ACN or ARBN Quarter ended (“current quarter”)
75-070-028-625	31-Mar-16

Consolidated statement of cash flows

Consolidated statement of cash flows
Cash flows related to operating activities	Current quarter $A’000	Year to date (9 months) $A’000
1.2 Payments for (a) staff costs (b) advertising and marketing (c) research and development (excluding staff costs relating to R&D) (d) leased assets (e) other working capital 1.3 Dividends received 1.4 Interest and other items of a similar nature received 1.5 Interest and other costs of finance paid 1.6 Income taxes paid 1.1 Receipts from customers and government grants	7,395 (2,611) (139) (425) (90) (5,945) - 7 (57) -	7,871 (3,958) (521) (913) (90) (8,204) - 29 (57) -
Net operating cash flows	(1,865)	(5,843)

NOTES:

	Current quarter $A’000	Year to date (9 months) $A’000
1.8 Net operatingcash flows(carried forward)	(1,865)	(5,843)
Cash flows related to investing activities 1.9 Payment for acquisition of: (a) Businesses (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets Proceeds from disposal of: (a) Businesses (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets 1.11 Loans to other entities 1.12 Loans repaid by other entities 1.13 Adjustment for cash remaining in subsidiary entity at disposal Net investing cash flows 1.10	- (11,907) - (171) - - - - - - - - -	- (11,907) - (331) - - - - - - - - -
	(12,078)	(12,238)
1.14 Total operating and investing cash flows
	(13,943)	(18,081)
Cash flows related to financing activities 1.15 Proceeds from issues of shares, options, etc. 1.16 Proceeds from sale of forfeited shares 1.17 Proceeds from borrowings 1.18 Repayment of borrowings 1.19 Dividends paid 1.20 Other: Issue of converting notes Interest paid on converting notes Capital raising costs Net financing cash flows	6,235 - - 619 - 2,037 - (211)	12,468 - - 619 - 2,037 - (574)
	8,680	14,550
Net increase (decrease) in cash held 1.21 Cash at beginning of quarter/year to date 1.22 Exchange rate adjustments to item 1.20 1.23 Cash at end ofquarter
	(5,263) 10,591 -	(3,531) 8,858 -
	**5,328 **	5,328

NOTES:

1.20

Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities

Payments to related entities of the entity and associates of the	Payments to related entities of the entity and associates of the	related entities
1.24 Aggregate amount of payments to the parties included in item 1.2 1.25 Aggregate amount of loans to theparties included in item 1.11		Current quarter $A'000
		246
		NIL
1.26 Explanation necessary for an understanding of the transactions

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows The company acquired DIAsource Immunoassays SA on 11th January for €15,422,341. The acquisiton was financed by an initial payment of €7,722,341 ($11,907,468) with vendor finance of €7,700,000 payable over 4 years. The company allotted 9,789,733 Ordinary Shares at $0.075 each to vendors of DIAsource Immunoassays SA who elected to take shares in prepayment of interest $734,020 in accordance with the terms of the Share Purchase Agreement. The Company allotted 1,998,491 Ordinary Shares at $0.075 each to the convertible note lender 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

NIL

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

3.1 3.2 Credit standby arrangements Loan facilities	Amount available $A’000	Amount used $A’000
	NIL	NIL
	NIL	NIL
Reconciliation of cash

Reconciliation of cash	Reconciliation of cash
Reconciliation of cash at the end of the quarter (as shown in the consolidated		Current quarter	Previous quarter
statement of cash flows) to the related items in the accounts is as follows.
		$A’000	$A’000
4.1	Cash on hand and at bank	5,210	10,473
4.2	Deposits at call	118	118
4.3	Bank overdraft		-
4.4	Other - Funds held in trust re. Open Prospectus Offer		-
	Total: cash at end of quarter (item 1.23)	5,328	10,591
Acquisitions and disposals of business entities

		Acquisitions	Disposals
		(Item 1.9(a))	(Item 1.10(a))
5.1	Acquisition/disposal of subsidiary	DIAsource
		Immunoassays SA
5.2	Place of incorporation or registration	Belgium
5.3	Consideration for acquisition or disposal	€15,422,341
5.4	Total net assets at date of acquisition/disposal	€4,389,835
5.5	Nature of business	Manufacturer of
		diagnostic products

Compliance statement

1

This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act 2001 (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2 This statement does give a true and fair view of the matters disclosed.

Sign here:

Date: 28 April 2016

(Director)

Print name: Richard Martin